Quote this publication Share Print

PLEGRIDY (peginterferon beta-1a), disease modifying therapy for multiple sclerosis

NEUROLOGY - New medicinal product
Opinions on drugs - Posted on Aug 24 2015

Reason for request


No clinical benefit demonstrated in the treatment of the relapsing-remitting multiple sclerosis (RRMS) compared with existing treatments


  • PLEGRIDY has a Marketing Authorisation in the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
  • It is an alternative to other first-line disease modifying therapies indicated in RRMS.
  • Its efficacy versus placebo has been demonstrated. PLEGRIDY, administered subcutaneously once every 2 weeks, has not shown any clinical added value compared with available therapies.

Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments